CR20210305A - Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b] [1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa paar el tratamiento de la enfermedad de alzheimer - Google Patents

Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b] [1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa paar el tratamiento de la enfermedad de alzheimer

Info

Publication number
CR20210305A
CR20210305A CR20210305A CR20210305A CR20210305A CR 20210305 A CR20210305 A CR 20210305A CR 20210305 A CR20210305 A CR 20210305A CR 20210305 A CR20210305 A CR 20210305A CR 20210305 A CR20210305 A CR 20210305A
Authority
CR
Costa Rica
Prior art keywords
compounds
octan
azabicyclo
pyrrolo
triazol
Prior art date
Application number
CR20210305A
Other languages
English (en)
Inventor
Beat Frei
Hasane Ratni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20210305A publication Critical patent/CR20210305A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención proporciona derivados de 7-fenoxi-N-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5H-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados de la fórmula general (I) en donde R1, Ar, n y m son como se describen en la presente, composiciones que incluyen los compuestos, procesos de elaboración de los compuestos y los compuestos para su uso en los métodos de tratamiento médico. Los presentes compuestos son como moduladores de gamma-secretasa para el tratamiento de enfermedades asociadas al depósito de β-amiloide en el cerebro, tales como enfermedad de Alzheimer, angiopatía amiloide cerebral, sinaptopatía coclear, hipoacusia, hemorragia cerebral hereditaria con amiloidosis de tipo holandés (HCHWA-D), demencia multiinfarto, demencia pugilística y síndrome de Down. La presente descripción divulga la preparación de compuestos de ejemplo así como los datos farmacológicos de estos (por ejemplo, las páginas 54 a 74; los ejemplos 1 a 64; tabla). Un compuesto de ejemplo es, por ejemplo, (R)-7-(3,5-difluorofenoxi)-N-((1R,5S,8s)-3-(6-metoxipiridazin-4-il)-3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5Hpirrolo[1,2-b][1,2,4]triazol-2-amina (ejemplo 1).
CR20210305A 2018-12-13 2019-12-11 Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b] [1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa paar el tratamiento de la enfermedad de alzheimer CR20210305A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18212199 2018-12-13
PCT/EP2019/084538 WO2020120521A1 (en) 2018-12-13 2019-12-11 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CR20210305A true CR20210305A (es) 2021-07-20

Family

ID=64665266

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210305A CR20210305A (es) 2018-12-13 2019-12-11 Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b] [1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa paar el tratamiento de la enfermedad de alzheimer

Country Status (19)

Country Link
US (1) US20220056036A1 (es)
EP (1) EP3894411A1 (es)
JP (1) JP2022513466A (es)
KR (1) KR20210102900A (es)
CN (2) CN117946116A (es)
AR (1) AR116906A1 (es)
AU (1) AU2019395774A1 (es)
BR (1) BR112021009443A2 (es)
CA (1) CA3117870A1 (es)
CL (1) CL2021001547A1 (es)
CO (1) CO2021006837A2 (es)
CR (1) CR20210305A (es)
IL (2) IL310081A (es)
MA (1) MA54447A (es)
MX (1) MX2021006761A (es)
PE (1) PE20211776A1 (es)
SG (1) SG11202103340PA (es)
TW (1) TWI831892B (es)
WO (1) WO2020120521A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP3347363B1 (en) * 2015-09-09 2020-01-01 H. Hoffnabb-La Roche Ag N-(3-azabicyclo[3.2.1]octan-8-yl)-8-(4-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[l,5-a]pyridin-2-amine derivatives as gamma-secretase modulators for treating alzheimer's disease
CN108137579B (zh) * 2015-12-10 2022-01-07 豪夫迈·罗氏有限公司 桥连哌啶衍生物
EP3475279B1 (en) * 2016-06-27 2021-07-14 F. Hoffmann-La Roche AG Triazolopyridines as gamma-secretase modulators
CN109641912B (zh) * 2016-11-01 2021-10-29 豪夫迈·罗氏有限公司 二环杂芳基衍生物
US11319314B2 (en) * 2016-11-08 2022-05-03 Hoffmann-La Roche Inc. Phenoxytriazoles
AU2017376109A1 (en) 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy

Also Published As

Publication number Publication date
EP3894411A1 (en) 2021-10-20
AR116906A1 (es) 2021-06-23
MA54447A (fr) 2022-03-23
CL2021001547A1 (es) 2021-12-24
IL283823B1 (en) 2024-03-01
JP2022513466A (ja) 2022-02-08
SG11202103340PA (en) 2021-04-29
CA3117870A1 (en) 2020-06-18
PE20211776A1 (es) 2021-09-08
IL283823A (en) 2021-07-29
KR20210102900A (ko) 2021-08-20
WO2020120521A1 (en) 2020-06-18
CN113179641A (zh) 2021-07-27
CO2021006837A2 (es) 2021-06-10
IL310081A (en) 2024-03-01
MX2021006761A (es) 2021-07-15
BR112021009443A2 (pt) 2021-08-17
AU2019395774A1 (en) 2021-04-08
TWI831892B (zh) 2024-02-11
US20220056036A1 (en) 2022-02-24
CN117946116A (zh) 2024-04-30
TW202039499A (zh) 2020-11-01
CN113179641B (zh) 2024-01-02

Similar Documents

Publication Publication Date Title
NZ592685A (en) Modulators of cystic fibrosis transmembrane conductance regulator
NZ612041A (en) Compounds and their use as bace inhibitors
RU2013138733A (ru) Конденсированные производные аминодигидротиазина
PH12015501878A1 (en) Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
NZ601150A (en) Novel substituted bicyclic triazole derivatives as gamma secretase modulators
EA023824B1 (ru) ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE)
NZ605486A (en) Spiro-cyclic amine derivatives as s1p modulators
NZ629453A (en) Thiazole derivatives as alpha 7 nachr modulators
MX2017013483A (es) Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1).
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX343788B (es) Derivados de heteroarilo como moduladores de nachr alfa 7.
WO2006026204A3 (en) Novel gamma-lactams as beta-secretase inhibitors
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
SI2875011T1 (en) 5-HT3 receptor antagonists
MX344696B (es) Derivados de pirrol como moduladores de los receptores de acetilcolina nicotinicos para su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer y la enfermedad de parkinson.
MX2022006470A (es) Tiromimeticos novedosos.
MX2012003720A (es) N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos.
WO2021012049A8 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
SA518400501B1 (ar) مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل)
PE20212113A1 (es) Inhibidores de moleculas pequenas de la familia de quinasas jak
PH12019501968A1 (en) PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
PH12020550761A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
CR20210305A (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b] [1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa paar el tratamiento de la enfermedad de alzheimer